Canagliflozin vs Dapagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson and partners
NCT01032629 · Phase 3 · completed
The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.
Next expected readout: December 2026 · NCT05427084 (registry estimate)
Reported efficacy
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline (Day 1) and Week 26); Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)): Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). (met)
Result source: NCT03170518
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca and partners
NCT00528372 · Phase 3 · completed
The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) (met)
Result source: NCT01392677
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Canagliflozin | Dapagliflozin |
|---|---|---|
| HbA1c, change | -0.4% vs 0.4%−0.8 vs placeboNCT0317051841 other results
| -0.9% vs -0.2%−0.7 vs placeboNCT0052837250 other results
|
| Body weight, change (kg) | -2.9 vs -0.8−2.1 vs placeboNCT006422788 other results
| -3.2 vs -2.2−1 vs placeboNCT0052837240 other results
|
| HbA1c below 7% | 42.8% vs 43%vs Metformin XRNCT018093276 other results
| 50.8% vs 31.6%+19.2 vs placeboNCT0052837217 other results
|
| Fasting plasma glucose, change | -0.6 vs 0.2−0.7 vs placeboNCT0103262934 other results
| -1.3 vs 0.2−1.5 vs placeboNCT0098486734 other results
|
| 3-point MACE (% with event) | —Not posted · NCT04304261 | —Not posted · NCT04170998 |
HbA1c, change
- Canagliflozin
- -0.4% vs 0.4%−0.8 vs placeboNCT03170518
41 other results
- -0.7% vs -0.0% NCT01106651
- -0.4% vs -0.0% NCT01064414
- -1.0% vs -0.3% NCT01106690
- -1.1% vs -0.1% NCT01106625
- -1.0% vs 0.1% NCT01081834
- -1.1% vs -0.5% NCT01381900
- -0.6% vs -0.0% NCT01106651
- -0.3% vs -0.0% NCT01064414
- -0.9% vs -0.3% NCT01106690
- -0.8% vs -0.1% NCT01106625
- -0.8% vs 0.1% NCT01081834
- -1.0% vs -0.5% NCT01381900
- -1.0% vs -0.1% NCT02354235
- -0.9% vs -0.8% NCT00968812
- -1.0% vs -0.7% NCT01137812
- -1.4% vs -1.3% NCT01809327
- -0.9% vs -0.8% NCT01106677
- -0.8% vs -0.8% NCT00968812
- -1.4% vs -1.3% NCT01809327
- -0.8% vs -0.8% NCT01106677
- -1.8% vs -1.3% NCT01809327
- -1.8% vs -1.3% NCT01809327
- -0.3% vs 0.0% NCT01032629
- -0.3% vs 0.0% NCT01032629
- -0.3% vs 0.7% NCT03170518
- -0.6% vs 0.1% NCT03170518
- -0.9% vs -0.7% NCT01106677
- -0.7% vs -0.6% NCT00968812
- -0.7% vs -0.7% NCT01106677
- -0.7% vs -0.6% NCT00968812
- -0.9% vs -0.2% NCT00642278
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.2% NCT00642278
- -0.7% vs -0.2% NCT00642278
- -0.6% vs -0.0% NCT01340664
- -0.5% vs -0.0% NCT01340664
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.0% NCT02025907
- -1.0% vs 0.1% NCT02220920
- -0.9% vs -1.1% NCT02622113
- 7.8% vs 8.3% NCT02964585
- Dapagliflozin
- -0.9% vs -0.2%−0.7 vs placeboNCT00528372
50 other results
- -0.8% vs -0.2% NCT00528372
- -0.9% vs -0.2% NCT01392677
- -0.9% vs -0.3% NCT00673231
- -0.8% vs -0.3% NCT00673231
- -0.8% vs -0.3% NCT00673231
- -0.6% vs 0.1% NCT00357370
- -0.7% vs 0.1% NCT00357370
- -0.8% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.6% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.8% vs -0.3% NCT00528879
- -0.8% vs -0.1% NCT00680745
- -1.0% vs -0.4% NCT00683878
- -0.7% vs -0.3% NCT00528879
- -0.6% vs -0.1% NCT00680745
- -0.8% vs -0.4% NCT00683878
- -0.7% vs -0.3% NCT00528879
- -0.6% vs -0.1% NCT00680745
- -0.6% vs 0.4% NCT03199053
- -0.5% vs 0.0% NCT00984867
- -1.2% vs -1.4% NCT00643851
- -2.0% vs -1.4% NCT00643851
- -0.5% vs -0.5% NCT00660907
- -2.0% vs -1.4% NCT00859898
- -1.4% vs -1.4% NCT00859898
- -0.9% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.7% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.6% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.9% vs -0.3% NCT00528879
- -0.7% vs -0.3% NCT00528879
- -0.7% vs -0.3% NCT00528879
- -2.0% vs 0.2% NCT00528372
- -1.2% vs 0.2% NCT00528372
- -1.4% vs -0.5% NCT00528879
- -0.8% vs 0.0% NCT00984867
- -2% vs 0.2% NCT00528372
- -1.5% vs 0.2% NCT00528372
- -1.3% vs 0.2% NCT00528372
- -1.4% vs 0.2% NCT00528372
- -1.3% vs -0.5% NCT00528879
- -1.2% vs -0.5% NCT00528879
- -1.7% vs -1.8% NCT00643851
- -3.0% vs -1.8% NCT00643851
- -2.6% vs -2.0% NCT00859898
- -2.1% vs -2.0% NCT00859898
- -1% vs -0.5% NCT02564926
Body weight, change (kg)
- Canagliflozin
- -2.9 vs -0.8−2.1 vs placeboNCT00642278
8 other results
- -1.5 vs 0.1 NCT01939496
- -2.3 vs -0.8 NCT00642278
- -1.0 vs 0.1 NCT01939496
- -2.9 vs -0.8 NCT00642278
- -2.3 vs -0.8 NCT00642278
- -2.0 vs -0.8 NCT00642278
- -3.5 vs -1.9 NCT02324842
- -6 vs -1.9 NCT02324842
- Dapagliflozin
- -3.2 vs -2.2−1 vs placeboNCT00528372
40 other results
- -3.0 vs -2.2 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -2.6 vs -0.6 NCT01392677
- -1.7 vs 0.0 NCT00673231
- -1.0 vs 0.0 NCT00673231
- -1.0 vs 0.0 NCT00673231
- -2.8 vs -2.2 NCT00528372
- -3.5 vs -2.2 NCT00528372
- -2.9 vs -2.4 NCT00528372
- -3.7 vs -2.4 NCT00528372
- -3.3 vs -2.2 NCT00528372
- -3.8 vs -2.2 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -4.3 vs -2.4 NCT00528372
- -2.9 vs -0.9 NCT00528879
- -3.1 vs -1.0 NCT00528879
- -2.3 vs -0.7 NCT00680745
- -2.5 vs -0.8 NCT00680745
- -0.1 vs 1.6 NCT00683878
- -0.1 vs 1.8 NCT00683878
- -3.0 vs -0.9 NCT00528879
- -3.2 vs -1.0 NCT00528879
- -1.6 vs -0.7 NCT00680745
- -1.7 vs -0.8 NCT00680745
- 0.1 vs 1.6 NCT00683878
- 0.3 vs 1.8 NCT00683878
- -2.2 vs -0.9 NCT00528879
- -2.4 vs -1.0 NCT00528879
- -1.2 vs -0.7 NCT00680745
- -1.2 vs -0.8 NCT00680745
- -2.1 vs -0.3 NCT00984867
- -2.6 vs -1.3 NCT00643851
- -2.9 vs -1.5 NCT00643851
- -2.7 vs -1.3 NCT00643851
- -3.0 vs -1.5 NCT00643851
- -3.2 vs 1.4 NCT00660907
- -3.3 vs -1.4 NCT00859898
- -2.7 vs -1.4 NCT00859898
- -2.4 vs 1.3 NCT02564926
HbA1c below 7%
- Canagliflozin
- 42.8% vs 43%vs Metformin XRNCT01809327
6 other results
- 38.8% vs 43% NCT01809327
- 56.8% vs 43% NCT01809327
- 49.6% vs 43% NCT01809327
- 57.1% vs 31.5% NCT01340664
- 47.8% vs 31.5% NCT01340664
- 32.3% vs 12.2% NCT02025907
- Dapagliflozin
- 50.8% vs 31.6%+19.2 vs placeboNCT00528372
17 other results
- 51.6% vs 31.6% NCT00528372
- 31.8% vs 11.1% NCT01392677
- 44.2% vs 31.6% NCT00528372
- 44% vs 31.6% NCT00528372
- 41.3% vs 31.6% NCT00528372
- 51.4% vs 31.6% NCT00528372
- 40.6% vs 25.9% NCT00528879
- 31.7% vs 13% NCT00680745
- 38.8% vs 22.4% NCT00683878
- 37.5% vs 25.9% NCT00528879
- 30.3% vs 13% NCT00680745
- 32.5% vs 22.4% NCT00683878
- 33% vs 25.9% NCT00528879
- 26.8% vs 13% NCT00680745
- 26.6% vs 10% NCT03199053
- 22.5% vs 34.6% NCT00643851
- 52.4% vs 34.6% NCT00643851
Fasting plasma glucose, change
- Canagliflozin
- -0.6 vs 0.2−0.7 vs placeboNCT01032629
34 other results
- -0.4 vs 0.2 NCT01032629
- -1.1 vs 0.4 NCT01106651
- -0.7 vs 0.0 NCT01064414
- -1.8 vs 0.1 NCT01106690
- -1.7 vs 0.2 NCT01106625
- -1.9 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1 vs 0.4 NCT01106651
- -0.8 vs 0.0 NCT01064414
- -1.5 vs 0.1 NCT01106690
- -1.0 vs 0.2 NCT01106625
- -1.5 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1.9 vs 0.2 NCT02354235
- -2.1 vs -1.1 NCT01106677
- -1.9 vs -1.0 NCT01106677
- -1.7 vs -0.3 NCT01137812
- -1.5 vs -1.1 NCT01106677
- -1.4 vs -1.0 NCT01106677
- 9.7 vs 9.8 NCT02324842
- 10.0 vs 9.8 NCT02324842
- -1.4 vs 0.2 NCT00642278
- -1.3 vs -0.4 NCT01939496
- -1.4 vs 0.2 NCT00642278
- -0.0 vs -0.4 NCT01939496
- -1.3 vs 0.2 NCT00642278
- -1.5 vs 0.2 NCT00642278
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.2 NCT00642278
- -1.6 vs -0.1 NCT02025907
- -1.9 vs -0.1 NCT02220920
- -1.8 vs -1.8 NCT02622113
- 7.9 vs 8.8 NCT02964585
- Dapagliflozin
- -1.3 vs 0.2−1.5 vs placeboNCT00984867
34 other results
- -1.6 vs -0.2 NCT00528372
- -1.6 vs -0.2 NCT00528372
- -1.9 vs -0.0 NCT01392677
- -1.2 vs 0.2 NCT00673231
- -1.0 vs 0.2 NCT00673231
- 0.1 vs 1.0 NCT00357370
- -0.9 vs -0.1 NCT00528372
- -0.7 vs 0.2 NCT00673231
- -1.1 vs -0.1 NCT00528372
- -0.5 vs 1.0 NCT00357370
- -1.3 vs -0.2 NCT00528372
- -1.5 vs -0.2 NCT00528372
- -0.9 vs -0.1 NCT00528372
- -1.0 vs -0.1 NCT00528372
- -0.8 vs -0.2 NCT00528372
- -1.4 vs -0.2 NCT00528372
- -0.2 vs -0.1 NCT00528372
- -1.6 vs -0.1 NCT00680745
- -0.8 vs -0.1 NCT00528372
- -1.3 vs -0.3 NCT00528879
- -1.6 vs -0.3 NCT00683878
- -0.9 vs 0.1 NCT00528879
- -1.2 vs -0.3 NCT00528879
- -1.2 vs -0.1 NCT00680745
- -1.4 vs -0.3 NCT00683878
- -0.7 vs 0.1 NCT00528879
- -1.0 vs -0.3 NCT00528879
- -0.9 vs -0.1 NCT00680745
- -0.3 vs 0.1 NCT00528879
- -0.6 vs 0.5 NCT03199053
- -2.3 vs -1.9 NCT00643851
- -3.4 vs -1.9 NCT00643851
- -3.4 vs -1.9 NCT00859898
- -2.6 vs -1.9 NCT00859898
3-point MACE (% with event)
- Canagliflozin
- —Not posted · NCT04304261
- Dapagliflozin
- —Not posted · NCT04170998
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. Canagliflozin: 13 of 13 rows · Dapagliflozin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Canagliflozin Rows use multiple source trials | Dapagliflozin Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -0.7 vs -0.5 placebo kg @ 52wk100/300 mga,b,c NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 | -0.91 vs 0.46 Glimepiride kg @ 52wka,b,c NCT02564926 · Phase 4 · registry result, not featured evidence |
| Body Fat percent change · % of baseline | -1.18% (n=60) vs 0.02% (n=50) placebo @ 26wk300 mgd,a,b,c,e NCT01106651 · Phase 3 · registry result, not featured evidence show 1 more dose-1.04% (n=56) vs 0.02% (n=50) placebo @ 26wk100 mg NCT01106651 · Phase 3 · registry result, not featured evidence | -1.21% (n=56) vs 0.73% (n=56) Glimepiride @ 52wka,b,c,e NCT02564926 · Phase 4 · registry result, not featured evidence |
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -4.79 mmol/L @ 26wk*300 mgd,b,c NCT01081834 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -86.3 mg/dL as posted show 1 more dose-4.53 mmol/L @ 26wk*100 mg NCT01081834 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -81.7 mg/dL as posted | -1.62 mmol/L @ 26wk10 mgd,b,c NCT03199053 · Phase 3 show 1 more dose-0.98 mmol/L @ 26wk5 mg NCT03199053 · Phase 3 |
| HbA1c absolute value · percentage points | 8.2% (n=15) vs 8.4% (n=15) Liraglutide @ 16wkd,f,b,g NCT02324842 · Phase na · registry result, not featured evidence show 1 more dose8.1% (n=15) vs 8.4% (n=15) Liraglutide @ 16wk NCT02324842 · Phase na · registry result, not featured evidence · combination | 7.4% (n=31) vs 8% (n=31) placebo @ 52wkf,b,g NCT03782259 · Phase 4 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.56% (n=43) @ 26wk300 mgd,b,c NCT01081834 · Phase 3 · registry result, not featured evidence show 1 more dose-2.13% (n=46) @ 26wk100 mg NCT01081834 · Phase 3 · registry result, not featured evidence | -0.74% (n=19) @ 26wk10 mgd,b,c NCT03199053 · Phase 3 show 1 more dose-0.71% (n=21) @ 26wk5 mg NCT03199053 · Phase 3 |
| HbA1c Less Than 7 absolute value · percentage points | 47.6% (n=374) vs 35.3% (n=365) Sitagliptin @ 52wk300 mgb,h NCT01137812 · Phase 3 · registry result, not featured evidence | 31.7% (n=216) vs 35.5% (n=203) Metformin XR @ 24wkd,b,h NCT00859898 · Phase 3 show 1 more dose46.6% (n=202) vs 35.5% (n=203) Metformin XR @ 24wk NCT00859898 · Phase 3 · combination |
| PPG 2h Change mg/dL absolute change · mmol/L | -3.34 vs -0.51 placebo mmol/L @ 24wk*b NCT02354235 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -60.1 mg/dL as posted | -3.75 vs -0.78 placebo mmol/L @ 24wk*10MGd,b NCT00683878 · Phase 3 · combination · converted to mmol/L from -67.5 mg/dL as posted show 1 more dose-3.61 vs -0.78 placebo mmol/L @ 24wk*5MG NCT00683878 · Phase 3 · combination · converted to mmol/L from -65.1 mg/dL as posted |
| SBP absolute change · mmHg | -4.65 vs -0.66 Sitagliptin mmHg @ 52wk300 mgd,a,b,c NCT01106677 · Phase 3 · registry result, not featured evidence show 1 more dose-3.53 vs -0.66 Sitagliptin mmHg @ 52wk100 mg NCT01106677 · Phase 3 · registry result, not featured evidence | -2.18 vs 4.63 Glimepiride mmHg @ 52wka,b,c NCT02564926 · Phase 4 · registry result, not featured evidence |
| Seated SBP absolute change · mmHg | 0 vs 1.5 placebo mmHg @ 52wk100/300 mgi,c,j NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 | -4.04 vs -0.27 placebo mmHg @ 8wk10 mgi,c,j NCT01392677 · Phase 3 · combination 1 other source trial-5.98 vs -5.12 placebo mmHg @ 8wk NCT00984867 · Phase 3 |
| Dropout rate | 6.1%300 mgk NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results7%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 33.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 29%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 0.7%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence 1.2% NCT01989754 · Phase 4 · registry result, not featured evidence 13.2% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 11.1% NCT02025907 · Phase 4 · registry result, not featured evidence 3.9% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 3.6%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 5.3%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 9.2%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 11%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 10.5%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 5.1%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 24.6%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 23.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 5.3%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 4%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 7.9%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 16.7%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.4%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 8%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 12%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 12.5%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 17.3%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 17.8%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 32.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 14%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 8.6%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 12.5%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 10.9%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 13.8%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 13.3%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | 18.6%10 mg AMl NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results14.5%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.8%10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 18.8%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 16.2%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6%5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.7%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 13.4%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 0%20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 14.2%Dapagliflozin NCT00859898 · Phase 3 13.3%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 16.3%5 mg NCT00643851 · Phase 3 8.8%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 11.9%10 mg NCT00528879 · Phase 3 · combination 10.9%5 mg NCT00528879 · Phase 3 · combination —5.0 mg NCT00528879 · Phase 3 · combination 12.4%2.5 mg NCT00528879 · Phase 3 · combination 20.7% NCT00660907 · Phase 3 · combination 6.6%10 mg NCT00680745 · Phase 3 · combination 9%5 mg NCT00680745 · Phase 3 · combination 9.1%2.5 mg NCT00680745 · Phase 3 · combination 7.3%10 mg NCT01392677 · Phase 3 · combination 10%10MG NCT00683878 · Phase 3 · combination 11.3%5MG NCT00683878 · Phase 3 · combination 7.6% NCT00984867 · Phase 3 9.2%10mg NCT00673231 · Phase 3 12.3%5mg NCT00673231 · Phase 3 10.9%2.5mg NCT00673231 · Phase 3 2.5%10mg QD NCT02413398 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 · combination —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 6.2%Dapagliflozin NCT03199053 · Phase 3 · background therapy 1.3%10 mg NCT01730534 · Phase 3 16.7%Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence 16.7%Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence 0%T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence 0%Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence 0%Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination 12.9% NCT03782259 · Phase 4 · registry result, not featured evidence 16% NCT02235298 · Phase 4 · registry result, not featured evidence — NCT02796170 · Phase 4 · registry result, not featured evidence —10mg NCT03338855 · Phase 4 · registry result, not featured evidence — NCT02973477 · Phase 4 · registry result, not featured evidence 7.4%10 mg NCT03387683 · Phase 4 · registry result, not featured evidence 7.7% NCT02433678 · Phase 4 · registry result, not featured evidence 0%10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence 8.3% NCT03074630 · Phase 4 · registry result, not featured evidence 13.3% NCT02564926 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —300 mgk NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results—100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.5%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT02065791 · Phase 3 — NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence — NCT01989754 · Phase 4 · registry result, not featured evidence 5.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 0.9% NCT02025907 · Phase 4 · registry result, not featured evidence 1.3% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 4.6% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.3%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 3.4%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 1.7%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 9.7%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.1%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 4.4%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 0.9%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 1.6%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.9%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 7.5%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.1%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 3.1%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 4.7%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 3.1%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence —Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence —Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | 8.6%10 mg AMl NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results3.9%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.1%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 4.4%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.1%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 —20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 4.1%Dapagliflozin NCT00859898 · Phase 3 1.9%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 3%5 mg NCT00643851 · Phase 3 1%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 3%10 mg NCT00528879 · Phase 3 · combination 1.5%5 mg NCT00528879 · Phase 3 · combination —5.0 mg NCT00528879 · Phase 3 · combination 2.9%2.5 mg NCT00528879 · Phase 3 · combination 8.1% NCT00660907 · Phase 3 · combination 2%10 mg NCT00680745 · Phase 3 · combination 2.1%5 mg NCT00680745 · Phase 3 · combination 3.2%2.5 mg NCT00680745 · Phase 3 · combination 0.9%10 mg NCT01392677 · Phase 3 · combination 2.1%10MG NCT00683878 · Phase 3 · combination 2.1%5MG NCT00683878 · Phase 3 · combination 3.1% NCT00984867 · Phase 3 3.1%10mg NCT00673231 · Phase 3 4.2%5mg NCT00673231 · Phase 3 2.5%2.5mg NCT00673231 · Phase 3 —10mg QD NCT02413398 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 · combination —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —Dapagliflozin NCT03199053 · Phase 3 · background therapy —10 mg NCT01730534 · Phase 3 —Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence —Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence —Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence —T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence —Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence —Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination — NCT03782259 · Phase 4 · registry result, not featured evidence 4% NCT02235298 · Phase 4 · registry result, not featured evidence — NCT02796170 · Phase 4 · registry result, not featured evidence —10mg NCT03338855 · Phase 4 · registry result, not featured evidence — NCT02973477 · Phase 4 · registry result, not featured evidence —10 mg NCT03387683 · Phase 4 · registry result, not featured evidence — NCT02433678 · Phase 4 · registry result, not featured evidence —10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence — NCT03074630 · Phase 4 · registry result, not featured evidence — NCT02564926 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 42.1%300 mgk NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results41.6%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.7%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.7%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.9%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 33.5%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 17.6% NCT02920918 · Phase 4 · registry result, not featured evidence 24.6% NCT01989754 · Phase 4 · registry result, not featured evidence 9.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 7% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 1.9% NCT02025907 · Phase 4 · registry result, not featured evidence 4% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 1.4% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 3%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 18.2%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.4%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 16.6%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 1.8%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 23.6%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.1%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 20%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 6.1%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 7.1%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 2.7%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.8%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.2%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 4.5%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 2.3%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 1%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 2.5%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 0%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 6.4%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 3.2%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 0%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.6%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 0%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | 1.4%10 mg AMl NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results3.9%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.3%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 7.4%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.4%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 4.2%20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 2.3%Dapagliflozin NCT00859898 · Phase 3 1.4%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 4.4%5 mg NCT00643851 · Phase 3 3.1%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 10.4%10 mg NCT00528879 · Phase 3 · combination —5 mg NCT00528879 · Phase 3 · combination 6.6%5.0 mg NCT00528879 · Phase 3 · combination 10.9%2.5 mg NCT00528879 · Phase 3 · combination 8.6% NCT00660907 · Phase 3 · combination 6%10 mg NCT00680745 · Phase 3 · combination 6.9%5 mg NCT00680745 · Phase 3 · combination 7.1%2.5 mg NCT00680745 · Phase 3 · combination 0.9%10 mg NCT01392677 · Phase 3 · combination 1.4%10MG NCT00683878 · Phase 3 · combination 2.8%5MG NCT00683878 · Phase 3 · combination 4.4% NCT00984867 · Phase 3 7.1%10mg NCT00673231 · Phase 3 4.7%5mg NCT00673231 · Phase 3 7.4%2.5mg NCT00673231 · Phase 3 5.6%10mg QD NCT02413398 · Phase 3 0%10 mg NCT03199053 · Phase 3 4.8%10 mg NCT03199053 · Phase 3 0%10 mg NCT03199053 · Phase 3 · combination 1.2%5 mg NCT03199053 · Phase 3 0%5 mg NCT03199053 · Phase 3 9.1%5 mg NCT03199053 · Phase 3 —Dapagliflozin NCT03199053 · Phase 3 · background therapy 37.4%10 mg NCT01730534 · Phase 3 0%Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence 0%T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence 0%Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence 0%Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination — NCT03782259 · Phase 4 · registry result, not featured evidence 0% NCT02235298 · Phase 4 · registry result, not featured evidence 0% NCT02796170 · Phase 4 · registry result, not featured evidence 0%10mg NCT03338855 · Phase 4 · registry result, not featured evidence 2.3% NCT02973477 · Phase 4 · registry result, not featured evidence 0%10 mg NCT03387683 · Phase 4 · registry result, not featured evidence 0% NCT02433678 · Phase 4 · registry result, not featured evidence 0%10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence — NCT03074630 · Phase 4 · registry result, not featured evidence 10% NCT02564926 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | 300 mgk hypoglycaemia 14.6% (placebo 12.1%) nasopharyngitis 14.1% (placebo 15.3%) urinary tract infection 11% (placebo 8.9%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 59 more results100 mg nasopharyngitis 15.6% (placebo 15.3%) hypoglycaemia 12.5% (placebo 12.1%) upper respiratory tract infection 10.9% (placebo 11.3%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 11.3% diarrhoea 8% upper respiratory tract infection 7.8% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 7.6% diarrhoea 6.8% upper respiratory tract infection 5.6% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 9.7% urinary tract infection 9.1% upper respiratory tract infection 7.5% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 6.8% back pain 6% urinary tract infection 5.4% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg urinary tract infection 29.4% (placebo 4.6%) urinary tract infection 29.4% (placebo 4.6%) nausea 11.8% (placebo 1.1%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg headache 11.9% (placebo 3.4%) headache 11.9% (placebo 3.4%) nasopharyngitis 11.9% (placebo 5.7%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg hypoglycaemia 9.7% (placebo 10.3%) urinary tract infection 9.2% (placebo 8.4%) hypertension 6.5% (placebo 8.8%) NCT02065791 · Phase 3 300 mg fatigue 3.2% diarrhoea 1.6% discomfort 1.6% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 17.6% hypotensive event 11.8% arrhythmic events 5.9% NCT02920918 · Phase 4 · registry result, not featured evidence balanoposthitis 3.2% (placebo 0.9%) NCT01989754 · Phase 4 · registry result, not featured evidence blood glucose decreased 40% (placebo 23.9%) hypoglycaemia 38.7% (placebo 32.8%) nasopharyngitis 34.7% (placebo 25.4%) NCT02622113 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 33.8% gastroenteritis 9.9% hypoglycaemia 9.9% NCT02227849 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 5.6% (placebo 5.6%) back pain 2.8% (placebo 0.9%) depression 2.8% (placebo 0%) NCT02025907 · Phase 4 · registry result, not featured evidence blood glucose decreased 26.7% (placebo 16.9%) hypoglycaemia 25.3% (placebo 21.1%) nasopharyngitis 16% (placebo 18.3%) NCT02220920 · Phase 4 · registry result, not featured evidence · combination 300 mg pollakiuria 5.4% (placebo 1.8%) nasopharyngitis 0% (placebo 0%) NCT01939496 · Phase 4 · registry result, not featured evidence 100 mg nasopharyngitis 5.3% (placebo 0%) pollakiuria 1.8% (placebo 1.8%) NCT01939496 · Phase 4 · registry result, not featured evidence nasopharyngitis 30.7% pollakiuria 6.5% constipation 5.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 18.6% (placebo 16.2%) NCT02354235 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 3.8% upper respiratory tract infection 2.5% back pain 2.1% NCT01809327 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 3.8% glomerular filtration rate decreased 2.5% influenza 2.5% NCT01809327 · Phase 3 · registry result, not featured evidence diarrhoea 4.2% headache 3% influenza 3% NCT01809327 · Phase 3 · registry result, not featured evidence · combination diarrhoea 4.2% headache 3.8% influenza 3.4% NCT01809327 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 18.6% (placebo 15.2%) hypoglycaemia 15.3% (placebo 19.8%) urinary tract infection 14.8% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 9.7% (placebo 19.8%) nasopharyngitis 8.1% (placebo 15.2%) urinary tract infection 7.2% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 18.7% (placebo 15.2%) hypoglycaemia 15.4% (placebo 19.8%) urinary tract infection 13.3% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 10.4% (placebo 19.8%) nasopharyngitis 9.5% (placebo 15.2%) influenza 5.8% (placebo 7.6%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 7.5% (placebo 4%) upper respiratory tract infection 5.7% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 9% (placebo 4%) upper respiratory tract infection 3.1% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 11.2% (placebo 4.4%) nasopharyngitis 7.9% (placebo 11.1%) urinary tract infection 7.9% (placebo 5.6%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 22.5% (placebo 4.4%) urinary tract infection 13.5% (placebo 5.6%) nasopharyngitis 10.1% (placebo 11.1%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 14.4% (placebo 4.4%) arthralgia 4.4% (placebo 2.2%) bronchitis 4.4% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 20% (placebo 4.4%) arthralgia 5.6% (placebo 2.2%) bronchitis 5.6% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 9.6% (placebo 5.2%) pollakiuria 6.1% (placebo 0.9%) arthralgia 5.3% (placebo 1.7%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 13.2% (placebo 5.2%) arthralgia 7.9% (placebo 1.7%) urinary tract infection 7.9% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 8% (placebo 6.1%) back pain 7.1% (placebo 2.6%) nasopharyngitis 5.3% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 12.4% (placebo 6.1%) nasopharyngitis 9.7% (placebo 5.2%) back pain 8.8% (placebo 2.6%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 4.9% upper respiratory tract infection 4.9% urinary tract infection 3.5% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.3% upper respiratory tract infection 6.3% urinary tract infection 4.6% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg pollakiuria 5.7% urinary tract infection 4.9% nasopharyngitis 4.1% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 7.3% pollakiuria 5.7% headache 5.2% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.4% (placebo 3.2%) hypoglycaemia 5.8% (placebo 3.8%) nasopharyngitis 5.1% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 7.1% (placebo 3.2%) hypoglycaemia 7.1% (placebo 3.8%) nasopharyngitis 5.8% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 10.8% (placebo 6.4%) hypoglycaemia 7% (placebo 3.8%) urinary tract infection 5.7% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 13.4% (placebo 6.4%) hypoglycaemia 8.3% (placebo 3.8%) urinary tract infection 7.6% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 6.8% (placebo 5.2%) pain in extremity 6.8% (placebo 0%) urinary tract infection 4.5% (placebo 4.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 8.1% (placebo 5.2%) back pain 6.1% (placebo 3.1%) headache 6.1% (placebo 3.6%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 10.2% (placebo 5.2%) headache 8.6% (placebo 3.6%) back pain 7.6% (placebo 3.1%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 6.4% (placebo 4.2%) nasopharyngitis 4.3% (placebo 5.2%) pain in extremity 2.1% (placebo 0%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 7.2% (placebo 3.6%) urinary tract infection 7.2% (placebo 4.2%) nasopharyngitis 5.1% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 9.7% (placebo 3.6%) urinary tract infection 8.2% (placebo 4.2%) nasopharyngitis 7.2% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 17.5% nasopharyngitis 8.8% upper respiratory tract infection 8.8% NCT01137812 · Phase 3 · registry result, not featured evidence 300 mg daily headache 4.7% (placebo 3.1%) nausea 4.7% (placebo 0%) abdominal pain upper 3.1% (placebo 1.5%) NCT00642278 · Phase 2 · registry result, not featured evidence 100 mg daily headache 7.8% (placebo 3.1%) urinary tract infection 3.1% (placebo 6.2%) vulvovaginal mycotic infection 3.1% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence 300 mg twice daily nausea 7.8% (placebo 0%) abdominal pain upper 6.3% (placebo 1.5%) urinary tract infection 4.7% (placebo 6.2%) NCT00642278 · Phase 2 · registry result, not featured evidence 200 mg daily urinary tract infection 9.2% (placebo 6.2%) vulvovaginal mycotic infection 6.2% (placebo 0%) headache 3.1% (placebo 3.1%) NCT00642278 · Phase 2 · registry result, not featured evidence 50 mg daily nasopharyngitis 7.8% (placebo 3.1%) vulvovaginal mycotic infection 6.3% (placebo 0%) nausea 4.7% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence urinary frequency increased 86.7% dry mouth 26.7% light-headedness/dizziness 26.7% NCT02324842 · Phase na · registry result, not featured evidence nausea 53.3% dry mouth 40% constipation 33.3% NCT02324842 · Phase na · registry result, not featured evidence · combination | 10 mg AMl nasopharyngitis 14.3% (placebo 9.3%) arthralgia 8.6% (placebo 4%) headache 8.6% (placebo 12%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 42 more results10 mg PM headache 13.2% (placebo 12%) upper respiratory tract infection 11.8% (placebo 5.3%) back pain 9.2% (placebo 6.7%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg AM pharyngitis 9.4% (placebo 8%) arthralgia 7.8% (placebo 4%) headache 7.8% (placebo 12%) NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 5 mg PM headache 16.2% (placebo 12%) nasopharyngitis 13.2% (placebo 9.3%) arthralgia 11.8% (placebo 4%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg AM nasopharyngitis 16.9% (placebo 9.3%) influenza 10.8% (placebo 4%) arthralgia 9.2% (placebo 4%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg PM nasopharyngitis 16.4% (placebo 9.3%) abdominal pain 9% (placebo 2.7%) dizziness 9% (placebo 2.7%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg back pain 12.5% (placebo 8.7%) headache 12.5% (placebo 8.7%) fatigue 8.3% (placebo 0%) NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 20 mg nausea 12.5% (placebo 4.3%) pollakiuria 12.5% (placebo 17.4%) vomiting 12.5% (placebo 0%) NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 diarrhoea 7.1% vulvovaginal mycotic infection 3.3% urinary tract infection 2.8% NCT00859898 · Phase 3 · combination 5 mg dyslipidaemia 5.4% upper respiratory tract infection 4.9% urinary tract infection 4.4% NCT00643851 · Phase 3 10 mg back pain 13.3% (placebo 8%) influenza 12.6% (placebo 10.9%) diarrhoea 11.9% (placebo 7.3%) NCT00528879 · Phase 3 · combination 5.0 mg influenza 14.6% (placebo 10.9%) headache 9.5% (placebo 5.8%) arthralgia 7.3% (placebo 5.1%) NCT00528879 · Phase 3 · combination 2.5 mg influenza 13.9% (placebo 10.9%) nasopharyngitis 11.7% (placebo 8.8%) back pain 8% (placebo 8%) NCT00528879 · Phase 3 · combination 10 mg hypoglycemia 7.9% (placebo 4.8%) nasopharyngitis 3.3% (placebo 2.7%) hypertension 1.3% (placebo 4.1%) NCT00680745 · Phase 3 · combination 5 mg hypoglycemia 6.9% (placebo 4.8%) nasopharyngitis 5.5% (placebo 2.7%) hypertension 1.4% (placebo 4.1%) NCT00680745 · Phase 3 · combination 2.5 mg hypoglycemia 7.1% (placebo 4.8%) hypertension 5.2% (placebo 4.1%) nasopharyngitis 1.9% (placebo 2.7%) NCT00680745 · Phase 3 · combination 10MG dyslipidaemia 9.3% (placebo 4.3%) nasopharyngitis 7.9% (placebo 3.6%) diarrhoea 6.4% (placebo 4.3%) NCT00683878 · Phase 3 · combination 5MG upper respiratory tract infection 6.4% (placebo 5.8%) dyslipidaemia 5.7% (placebo 4.3%) nasopharyngitis 5% (placebo 3.6%) NCT00683878 · Phase 3 · combination nasopharyngitis 4% (placebo 6.2%) NCT00984867 · Phase 3 10mg hypoglycemia 44.9% (placebo 42.1%) nasopharyngitis 8.7% (placebo 11.2%) urinary tract infection 5.6% (placebo 3%) NCT00673231 · Phase 3 5mg hypoglycemia 47.6% (placebo 42.1%) nasopharyngitis 13.7% (placebo 11.2%) hypertension 6.1% (placebo 8.1%) NCT00673231 · Phase 3 2.5mg hypoglycemia 55% (placebo 42.1%) nasopharyngitis 13.9% (placebo 11.2%) hypertension 5.4% (placebo 8.1%) NCT00673231 · Phase 3 10 mg abdominal pain 4.8% (placebo 2.6%) abdominal pain upper 4.8% (placebo 0%) bronchitis 4.8% (placebo 0%) NCT03199053 · Phase 3 10 mg dysmenorrhoea 9.5% (placebo 2.6%) headache 9.5% (placebo 1.3%) conjunctivitis allergic 4.8% (placebo 0%) NCT03199053 · Phase 3 10 mg pharyngotonsillitis 14.3% (placebo 1.3%) tonsillitis 14.3% (placebo 0%) abdominal pain 0% (placebo 2.6%) NCT03199053 · Phase 3 · combination 5 mg headache 7.4% (placebo 1.3%) hypertriglyceridaemia 4.9% (placebo 1.3%) diarrhoea 3.7% (placebo 3.9%) NCT03199053 · Phase 3 5 mg headache 9.1% (placebo 1.3%) nasopharyngitis 3.6% (placebo 2.6%) anxiety 1.8% (placebo 0%) NCT03199053 · Phase 3 5 mg influenza 5.5% (placebo 2.6%) abdominal pain upper 3.6% (placebo 0%) headache 3.6% (placebo 1.3%) NCT03199053 · Phase 3 10 mg renal impairment 1.4% (placebo 1.7%) acute kidney injury 1% (placebo 1.3%) chronic kidney disease 0.9% (placebo 1.2%) NCT01730534 · Phase 3 genital mycotic infection 13.3% mild hypoglycemia 0% NCT02911792 · Phase 4 · registry result, not featured evidence genital mycotic infection 26.7% mild hypoglycemia 0% NCT02911792 · Phase 4 · registry result, not featured evidence transcient syncope 12.5% (placebo 0%) NCT02981966 · Phase 4 · registry result, not featured evidence transcient syncope 0% (placebo 0%) NCT02981966 · Phase 4 · registry result, not featured evidence nausea and vomiting 24% (placebo 0%) genital mycosis 0% (placebo 0%) NCT02981069 · Phase 4 · registry result, not featured evidence nausea and vomiting 20% (placebo 0%) genital mycosis 8% (placebo 0%) NCT02981069 · Phase 4 · registry result, not featured evidence · combination dysuria 12% (placebo 0%) frequency of urination 12% (placebo 0%) balanitis 2% (placebo 0%) NCT02235298 · Phase 4 · registry result, not featured evidence cold like symptoms 4.5% genital yeast infection 4.5% abrasion of left cornea 2.3% NCT02973477 · Phase 4 · registry result, not featured evidence 10mg Once Daily genital fungal infections 20.8% NCT02682563 · Phase 4 · registry result, not featured evidence nasopharyngitis 6.7% toothache 6.7% hypoglycaemia 5% NCT02564926 · Phase 4 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eAssessment timepoints differ: 52 weeks versus 26 weeks.
- fTrial phases differ: Phase 4 versus Phase na.
- gAssessment timepoints differ: 52 weeks versus 16 weeks.
- hAssessment timepoints differ: 24 weeks versus 52 weeks.
- iPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
- jAssessment timepoints differ: 8 weeks versus 52 weeks.
- kPopulation comparability has not been reviewed for 65 of these studies.
- lPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Canagliflozin
show 1 more result
show 2 more results
show 2 more results
show 33 more results
show 1 more result
+ 30 further endpoints in the CSV export.
Dapagliflozin
show 1 more result
show 8 more results
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 28 further endpoints in the CSV export.
Chronic Kidney Disease
Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson and partners
NCT02065791 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 4,401 participants with type 2 diabetes and diabetic nephropathy. Canagliflozin significantly lowered the rate of the composite renal/cardiovascular endpoint (kidney failure, doubling of creatinine, or renal/CV death) compared with placebo, with a hazard ratio of 0.70.
Next expected readout: December 2026 · NCT05507892 (registry estimate)
Reported efficacy
Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029) (met)
Result source: NCT03436693
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca and partners
NCT03036150 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial measuring a hard clinical composite of kidney failure and death, and dapagliflozin significantly reduced this composite compared with placebo.
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death. (Up to 38.2 months): Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001 (met)
Result source: NCT03036150
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Canagliflozin | Dapagliflozin |
|---|---|---|
| Kidney composite outcome | —Not reported | 6.6% vs 11.3%−4.7 vs placeboNCT03036150 |
| UACR, % change | 0.6% vs 1.2%−0.6 vs placeboNCT03436693 | -22.4% vs -1.8%−20.6 vs placeboNCT025479359 other results
|
| eGFR slope | —Not reported | —Not posted · NCT05998837 |
| Haemoglobin, change | —Not reported | —Not posted · NCT05998837 |
Kidney composite outcome
- Canagliflozin
- —Not reported
- Dapagliflozin
- 6.6% vs 11.3%−4.7 vs placeboNCT03036150
UACR, % change
- Canagliflozin
- 0.6% vs 1.2%−0.6 vs placeboNCT03436693
- Dapagliflozin
- -22.4% vs -1.8%−20.6 vs placeboNCT02547935
9 other results
- -39.1% vs -1.8% NCT02547935
- -34.3% vs 230.3% NCT04595370
- -58.0% vs 230.3% NCT04595370
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
- -34.3% vs 230.3% NCT04595370
- -58.0% vs 230.3% NCT04595370
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
eGFR slope
- Canagliflozin
- —Not reported
- Dapagliflozin
- —Not posted · NCT05998837
Haemoglobin, change
- Canagliflozin
- —Not reported
- Dapagliflozin
- —Not posted · NCT05998837
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Canagliflozin: 4 of 4 rows · Dapagliflozin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Canagliflozin | Dapagliflozin |
|---|---|---|
| Dropout rate | 0.7%100 mga NCT02065791 · Phase 3 show 1 more result19.5%100mg NCT03436693 · Phase 3 | —10 mga NCT03036150 · Phase 3 show 10 more results0.5%Dapagliflozin NCT03036150 · Phase 3 5.5%10 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence 3.2%10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 17.1%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 25%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 24.2%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 5.7%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 20.7%1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 9.9%0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT03190694 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —100 mga NCT02065791 · Phase 3 show 1 more result14.3%100mg NCT03436693 · Phase 3 | —10 mga NCT03036150 · Phase 3 show 10 more results—Dapagliflozin NCT03036150 · Phase 3 —10 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence —10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 2.9%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 8.3%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 12.1%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 0%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 3.9%1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 2.2%0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT03190694 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 33.5%100 mga NCT02065791 · Phase 3 show 1 more result27.9%100mg NCT03436693 · Phase 3 | 29.5%10 mga NCT03036150 · Phase 3 show 10 more results—Dapagliflozin NCT03036150 · Phase 3 8.3%10 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence 7.9%10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 12.1%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 5.9%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 9.7%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 3%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 5.6%1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 2.2%0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 1.9%10 mg NCT03190694 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mga hypoglycaemia 9.7% (placebo 10.3%) urinary tract infection 9.2% (placebo 8.4%) hypertension 6.5% (placebo 8.8%) NCT02065791 · Phase 3 show 1 more result100mg nasopharyngitis 35.1% (placebo 37%) hypoglycaemia 21.4% (placebo 20.8%) blood glucose decreased 17.5% (placebo 14.9%) NCT03436693 · Phase 3 | 10 mga nasopharyngitis 4.3% (placebo 3.8%) urinary tract infection 3.6% (placebo 3.7%) hypoglycaemia 3.4% (placebo 3.3%) NCT03036150 · Phase 3 show 9 more results10 mg nasopharyngitis 6.9% (placebo 4.1%) influenza 5.5% (placebo 1.4%) NCT02547935 · Phase 2/3 · registry result, not featured evidence 10 mg + 2.5 mg nasopharyngitis 6.6% (placebo 4.1%) influenza 1.3% (placebo 1.4%) NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 10 mg hyperkalaemia 9.1% (placebo 0%) urinary tract infection 9.1% (placebo 0%) fall 6.1% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence 150 mg + 10 mg nasopharyngitis 8.8% (placebo 0%) chronic kidney disease 5.9% (placebo 0%) diarrhoea 5.9% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 50 mg + 10 mg urinary tract infection bacterial 6.5% (placebo 0%) chronic kidney disease 3.2% (placebo 0%) hyperkalaemia 3.2% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 15 mg + 10 mg chronic kidney disease 3% (placebo 0%) colitis 0% (placebo 20%) diabetes mellitus 0% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 1.5 mg brain natriuretic peptide increased 5% (placebo 0.6%) headache 4.5% (placebo 1.1%) metabolic acidosis 3.9% (placebo 1.1%) NCT04724837 · Phase 2 · registry result, not featured evidence · combination 0.25 mg headache 6.6% (placebo 1.1%) hypertension 5.5% (placebo 0.6%) metabolic acidosis 5.5% (placebo 1.1%) NCT04724837 · Phase 2 · registry result, not featured evidence · combination 10 mg any adverse event 32.1% (placebo 25%) NCT03190694 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Canagliflozin
Dapagliflozin
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 3 more results
+ 4 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · Dapagliflozin's landscape